STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNYA
  4. [SCHEDULE 13G/A] Tenaya Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Tenaya Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock TNYA logo
Tenaya Therapeutics, Inc.

NASDAQ:TNYA

TNYA Rankings

#6665 Ranked by Market Cap
N/A Ranked by Dividends

TNYA Latest News

Jul 30, 2025
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
May 15, 2025
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 13, 2025
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
May 7, 2025
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 24, 2025
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

TNYA Latest SEC Filings

Jul 31, 2025
[SCHEDULE 13G/A] Tenaya Therapeutics, Inc. SEC Filing

TNYA Stock Data

109.08M
161.04M
0.72%
59.67%
6.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO